Current state and next-generation CAR-T cells in multiple myeloma
- 21 January 2022
- journal article
- review article
- Published by Elsevier in Blood Reviews
- Vol. 54, 100929
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy ResponsesScience Translational Medicine, 2013
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myelomaLeukemia, 2013
- Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cellsNature Biotechnology, 2012
- Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cellsCytotherapy, 2012
- Serum B‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survivalBritish Journal of Haematology, 2012
- Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor modelsBlood, 2012
- Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4Journal of Biological Chemistry, 2010
- In vitro expansion of gamma delta T cells with anti‐myeloma cell activity by Phosphostim and IL‐2 in patients with multiple myelomaBritish Journal of Haematology, 2007
- γδT cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surfaceBiochemical and Biophysical Research Communications, 2007
- BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma CellsJournal of Experimental Medicine, 2004